Lorundrostat Effective for Lowering BP in Uncontrolled Hypertension
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 15, 2023 -- The aldosterone synthase inhibitor lorundrostat is effective for lowering blood pressure among individuals with uncontrolled hypertension, according to a study published online Sept. 10 in the Journal of the American Medical Association to coincide with the American Heart Association Hypertension 2023 Scientific Sessions, held from Sept. 7 to 10 in Boston.
Luke J. Laffin, M.D., from the Cleveland Clinic Foundation, and colleagues compared the safety and efficacy of lorundrostat with placebo in a randomized trial among adults with uncontrolled hypertension taking two or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled and randomly assigned to placebo or one of five doses of lorundrostat; 37 participants with PRA greater than 1.0 ng/mL/h were subsequently enrolled and randomly assigned to placebo or lorundrostat 100 mg once daily.
The researchers observed changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg with 100, 50, and 12.5 mg once daily of lorundrostat and placebo, respectively, following eight weeks of treatment in participants with suppressed PRA. In individuals receiving twice-daily doses of 25 and 12.5 mg of lorundrostat, observed reductions in systolic blood pressure were −10.1 and −13.8 mm Hg, respectively. The least-squares mean difference in systolic blood pressure between placebo and treatment was −9.6 and −7.8 mm Hg, respectively, for the 50- and 100-mg once-daily dose. Systolic blood pressure decreased by 11.4 mm Hg among participants without suppressed PRA receiving 100 mg once-daily lorundrostat, which was similar to the blood pressure reduction with the same dose among those with suppressed PRA.
"The trial results support further study of lorundrostat as a treatment for uncontrolled hypertension," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Mineralys Therapeutics, which manufactures lorundrostat and funded the trial.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Novel Genetic Loci ID'd for Hypertension in European Ancestry
TUESDAY, May 7, 2024 -- A total of 113 novel genetic loci have been identified in the largest single-stage common variant genome-wide association study of blood pressure (BP)...
Long-Term Risk for MACE Increased for Children With Hypertension
TUESDAY, May 7, 2024 -- The long-term risk for major adverse cardiac events (MACE) is increased for children diagnosed with hypertension, according to a study published online May...
Intensive HTN Treatment Cuts Early T2D Diagnosis-Linked CVD Event Risk
MONDAY, April 29, 2024 -- More intensive hypertensive therapy significantly reduces the excess risk for cardiovascular disease (CVD) events associated with earlier hypertension...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.